UNICEF Will Act as Procurement / Logistics Agent for 220 Million Doses of COVID Vaccines from Johnson and Johnson for the African Union / African Vaccine Acquisition Trust in Addition to the 500 Million Doses Committed Under COVAX
The paragraphs below are excerpts. Click the links to read the full articles.
Slaughter and May
In a historic COVID-19 vaccine procurement agreement signed on 28 March 2021, all African Union Member States, through the African Vaccine Acquisition Trust (AVAT), will have access to 220 million doses of the Johnson & Johnson single-shot COVID-19 vaccine, with the potential to order an additional 180 million doses. The vaccines will be made available to African countries through the African Medical Supplies Platform (AMSP), over a period of 18 months. The transaction was made possible through the US$2 billion facility approved by Afreximbank, who also acted as Financial and Transaction Advisers, Guarantors, Instalment Payment Advisers and Payment Agents.
The successful conclusion of the Agreement was made possible by the support of the United Nations Economic Commission for Africa (ECA) and the United Nations International Children’s Emergency Fund (UNICEF), who supported the negotiation process with Johnson & Johnson. UNICEF is also acting as procurement and logistics agent. AVAT was supported in terms of advice on various aspects by the World Health Organization (WHO).
Washintgton Post
Johnson & Johnson announced a commitment Monday to supply 220 million doses of its coronavirus vaccine to 55 African countries, a step by the company toward plugging part of the vaccine gap between rich and poor nations.
The deal with the African Vaccine Acquisition Trust would make the first doses available beginning in the third quarter of this year. It carries an option for another 180 million doses, for a total of 400 million doses through 2022, the company said.
Johnson & Johnson did not disclose a price, but it has said it will not charge more than $10 a dose for its vaccine and intends not to make any profit on it during the pandemic. Johnson & Johnson has not yet disclosed projected vaccine revenue for 2021.
The drug giant also has committed to selling 500 million doses for Covax, the World Health Organization-affiliated program that is distributing vaccines to developing countries. The combined potential of 900 million doses for the developing world ranks U.S. firm Johnson & Johnson with British-Swedish company AstraZeneca as making some of the strongest commitments to help poor countries gain access to vaccine.
In a historic COVID-19 vaccine procurement agreement signed on 28 March 2021, all African Union Member States, through the African Vaccine Acquisition Trust (AVAT), will have access to 220 million doses of the Johnson & Johnson single-shot COVID-19 vaccine, with the potential to order an additional 180 million doses. The vaccines will be made available to African countries through the African Medical Supplies Platform (AMSP), over a period of 18 months. The transaction was made possible through the US$2 billion facility approved by Afreximbank, who also acted as Financial and Transaction Advisers, Guarantors, Instalment Payment Advisers and Payment Agents.
The successful conclusion of the Agreement was made possible by the support of the United Nations Economic Commission for Africa (ECA) and the United Nations International Children’s Emergency Fund (UNICEF), who supported the negotiation process with Johnson & Johnson. UNICEF is also acting as procurement and logistics agent. AVAT was supported in terms of advice on various aspects by the World Health Organization (WHO).
Washintgton Post
Johnson & Johnson announced a commitment Monday to supply 220 million doses of its coronavirus vaccine to 55 African countries, a step by the company toward plugging part of the vaccine gap between rich and poor nations.
The deal with the African Vaccine Acquisition Trust would make the first doses available beginning in the third quarter of this year. It carries an option for another 180 million doses, for a total of 400 million doses through 2022, the company said.
Johnson & Johnson did not disclose a price, but it has said it will not charge more than $10 a dose for its vaccine and intends not to make any profit on it during the pandemic. Johnson & Johnson has not yet disclosed projected vaccine revenue for 2021.
The drug giant also has committed to selling 500 million doses for Covax, the World Health Organization-affiliated program that is distributing vaccines to developing countries. The combined potential of 900 million doses for the developing world ranks U.S. firm Johnson & Johnson with British-Swedish company AstraZeneca as making some of the strongest commitments to help poor countries gain access to vaccine.
Comments
Post a Comment
If you are a member of XUNICEF, you can comment directly on a post. Or, send your comments to us at xunicef.news.views@gmail.com and we will publish them for you.